振东制药12月29日获融资买入888.82万元，融资余额3.51亿元

Group 1 - The core viewpoint of the news is that Zhendong Pharmaceutical experienced a decline in stock price and trading volume, with significant financing activities indicating a mixed investor sentiment [1][2]. - On December 29, Zhendong Pharmaceutical's stock fell by 1.18%, with a trading volume of 101 million yuan. The financing buy-in amount was 8.8882 million yuan, while the financing repayment was 8.5426 million yuan, resulting in a net financing buy of 345,600 yuan [1]. - As of December 29, the total balance of margin trading for Zhendong Pharmaceutical was 351 million yuan, which represents 6.03% of its circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of September 30, the number of shareholders for Zhendong Pharmaceutical was 48,400, an increase of 4.89% from the previous period, while the average circulating shares per person decreased by 4.66% to 20,762 shares [2]. - For the period from January to September 2025, Zhendong Pharmaceutical reported operating revenue of 2.215 billion yuan, a year-on-year decrease of 2.42%, and a net profit attributable to shareholders of 20.3641 million yuan, down 49.25% year-on-year [2]. - Since its A-share listing, Zhendong Pharmaceutical has distributed a total of 3.372 billion yuan in dividends, with no dividends paid in the last three years [3].